Rep. James Comer, R-Ky., on 23andMe information privateness considerations, his invitation for sanctuary governors to testify ahead of lawmakers and whether or not NPR and PBS must have investment stripped.
Regeneron Prescription drugs introduced on Monday that it’s going to gain “substantially all” of genetic trying out corporate 23andMe’s property.
The pharmaceutical corporate stated it gained the court-supervised public sale of the genetic trying out corporate, with Regeneron agreeing to pay $256 million for the property. 23andMe underwent the public sale as a part of the Bankruptcy 11 chapter coverage it filed in March to facilitate a sale of its industry.
In its chapter petition, the corporate had estimated a length of $100 million to $500 million for its property. Estimated liabilities have been the similar.
Genetics trying out corporate 23andMe filed for Bankruptcy 11 chapter coverage in March. ( Justin Sullivan/Getty Photographs / Getty Photographs)
Regeneron stated the do business in to buy 23andMe’s property will similar within the 3rd quarter of 2025, equipped it receives goodwill from the chapter courtyard overseeing the genetic trying out corporate’s Bankruptcy 11 chapter case. The do business in can be weighed via the courtyard in mid-June.
23ANDME FILES FOR BANKRUPTCY AS CALIFORNIA AG URGES CUSTOMERS TO DELETE DATA
The pharmaceutical corporate is purchasing 23andMe’s private genome carrier and its overall condition and analysis products and services areas, in line with 23andMe.
23andMe stated the do business in “includes Regeneron’s commitment to comply with the Company’s privacy policies and applicable law, process all customer personal data in accordance with the consents, privacy policies, and statements, terms of service, and notices currently in effect and have security controls in place designed to protect such data.”
| Ticker | Safety | Utmost | Alternate | Alternate % |
|---|---|---|---|---|
| REGN | REGENERON PHARMACEUTICALS INC. | 593.40 | -0.92 | -0.15% |
“Through our Regeneron Genetics Center, we have a proven track record of safeguarding personal genetic data, and we assure 23andMe customers that we will apply our high standards for safety and integrity to their data and ongoing consumer genetic services,” George Yancopoulos, co-chair of Regeneron’s board, stated in a observation.
Regeneron stated the do business in to buy 23andMe’s property will similar in 2025’s 3rd quarter. (Pavlo Gonchar/SOPA Photographs/LightRocket by the use of Getty Photographs / Getty Photographs)
“We believe we can help 23andMe deliver and build upon its mission to help people learn about their own DNA and how to improve their personal health, while furthering Regeneron’s efforts to improve the health and wellness of many,” he added.
23ANDME BANKRUPTCY: WILL YOUR PRIVATE DATA BE PROTECTED?
A court-appointed shopper privateness ombudsman will handover the courtyard with a document on June 10 next reviewing Regeneron’s proposed acquire of 23andMe and the “impact, if any, on consumers’ privacy,” 23andMe stated.
Regeneron desires to form 23andMe a “wholly owned or indirect” subsidiary of the corporate following the acquisition, with plans to uphold its private genomics carrier.
A court-appointed shopper privateness ombudsman will handover the courtyard with a document on June 10 next reviewing Regeneron’s proposed acquire of 23andMe and the “impact, if any, on consumers’ privacy,” 23andMe stated. (Smith Assortment/Gado/Getty Photographs / Getty Photographs)
“We are pleased to have reached a transaction that maximizes the value of the business and enables the mission of 23andMe to live on, while maintaining critical protections around customer privacy, choice and consent with respect to their genetic data,” 23andMe’s Mark Jensen stated.
23ANDME AGREES TO PAY $30M TO SETTLE LAWSUIT OVER 2023 DATA BREACH
23andMe additionally ran telehealth subsidiary Lemonaid Condition. That industry, which Regeneron isn’t purchasing, can be shuttered.
